Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BgRT and SBRT with Osimertinib in Oligoprogressive EGFR+ NSCLC
NCT06014827Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung carcinoma (NSCLC), sponsored by City of Hope. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT06014827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014827.